NASDAQ$BMEA
Biomea Fusion Inc · Q4 2026 earnings
Q4 2026 earnings · · After market close · Investor relations
Briefing
Biomea Fusion reported fiscal Q4 2026 no revenue, a net loss of $12.4M, and diluted loss per share of $0.17.
For the three months ended March 31, 2026 (fiscal Q4), Biomea had no product revenue. R&D was $9.1 million and G&A $3.7 million; net loss was $12.4 million ($0.17 loss per share) versus $29.3 million and $0.80 loss, reflecting reduced spend. Clinical-stage covalent kinase inhibitor programs continue.
- No revenue; R&D $9.1M (-60% YoY spend).
- Net loss narrowed to $12.4M from $29.3M.
- Diluted EPS loss $0.17 vs. $0.80.
- Warrant fair-value loss $0.6M.
- ICOVRI clinical development focus.
Headline financials
Revenue & EPS history
Biomea Fusion · Revenue · Quarterly
-$0.51
Forward guidance
Trial enrollment and financing runway in MD&A.
Tailwinds
- Operating loss narrowed sharply.
- Lower R&D burn rate.
Headwinds
- No commercial revenue.
- Still pre-profitability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q4 2026
+5.2%
Avg return
Earnings day
+3.3%
Avg return
5 days after
+3.0%
Avg return
30 days after
40%
8 / 20 earnings
Positive
+109.7%
Q4 2022
Best reaction
-16.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +15.3% | -13.5% | -23.7% | |
| Q3 2025 | -0.7% | -4.3% | -21.0% | |
| Q2 2025 | +0.6% | -3.2% | +21.5% | |
| Q1 2025 | -1.3% | -4.6% | +73.0% | |
| Q4 2024 | +1.2% | -7.8% | -8.7% | |
| Q3 2024 | -16.7% | -27.2% | -43.4% | |
| Q1 2024 | +6.7% | +3.7% | -9.1% | |
| Q4 2023 | -14.4% | -14.8% | -22.6% | |
| Q3 2023 | -6.8% | -7.9% | +16.3% | |
| Q2 2023 | -2.4% | -9.3% | -22.2% | |
| Q1 2023 | -3.3% | +2.6% | +12.5% | |
| Q4 2022 | +109.7% | +101.0% | +84.6% | |
| Q3 2022 | -15.6% | -29.4% | -43.3% | |
| Q2 2022 | +3.3% | +11.8% | +8.5% | |
| Q1 2022 | +35.2% | +69.4% | +127.2% | |
| Q4 2021 | -13.8% | -7.7% | -36.2% | |
| Q3 2021 | +7.6% | +2.0% | -7.9% | |
| Q2 2021 | -0.6% | -11.0% | -3.4% | |
| Q1 2021 | -0.3% | +7.9% | -21.4% | |
| Q4 2020 | -0.3% | +7.9% | -21.4% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro